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GENETIC SUSCEPTIBILITY TO ANTHRACYCLINE-RELATED CONGESTIVE
HEART FAILURE (A-CHF) IN SURVIVORS OF HEMATOPOIETIC CELL
TRANSPLANTATION (HCT)
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Hope; 3City of Hope
Background:HCTsurvivors are at increased risk for developing car-
diovascular disease, including A-CHF. We have demonstrated that
the risk of post-HCT A-CHF is primarily ascribed to pre-HCT ex-
posure to anthracyclines. This cardiotoxicity is dose-dependent,
with well-established modifying risk factors such as age at exposure
to anthracyclines, female gender, and mediastinal irradiation. How-
ever, thesemodifiers fail to explain the wide inter-individual variabil-
ity in the risk of A-CHF. Proposed pathogenesis of A-CHF includes
oxidative stress and metabolic derangements induced by intracardiac
anthracycline alcohol metabolites. Inherent susceptibility in these
pathways could explain the inter-individual variability in risk.
Methods:A nested case-control approachwas used. Individuals with
A-CHF with pre-HCT available germline DNA were identified
from patients transplanted at City of Hope between 1990-2007.
This cohort formed the sampling frame for selecting controls (with-
out A-CHF) matched on: age at HCT, type of HCT, ethnicity, an-
thracycline dose, and length of follow-up. We targeted functional
SNPs in genes involved in free radical metabolism (NAD[P]H oxi-
dase: subunits NCF4, RAC2, CYBA) as well as those impacting syn-
thesis of cardiotoxic anthracycline alcohol metabolites (carbonyl
reductase: CBR1 and CBR3).
Results:Twenty-two cases with A-CHFwere identified; median age
at HCT: 50.6 yrs; 82% autologous HCT; 73% non-Hispanic white;
median anthracycline dose: 300 mg/m2 (75-710); median time to A-
CHF: 2.4 yrs. Thirty-eight matched controls were identified. There
were no differences in gender, underlying diagnosis, pre-HCT me-
diastinal radiation, conditioning regimen, and BMI atHCTbetween
cases and controls. Multivariate conditional logistic regression re-
vealed that a polymorphism in the NAD(P)H oxidase subunit
RAC2 (rs13058338, 7508T/A) conferred a 3.2-fold risk of A-
CHF (Odds Ratio [OR]: 3.2; p 5 0.05), and there was a 10.8-fold
risk (OR: 10.8, p 5 0.04) for those with the GG genotype of
rs9024 (1096G/A) in CBR1.
Conclusion:Our findings support the ‘‘unifying hypothesis’’ that A-
CHF could develop as a result of oxidative stress or metabolic de-
rangements induced by cardiotoxic alcohol metabolites, and that
the high-risk variants of RAC2 and CBR1 play a critical role in mod-
ifying this risk. These data could facilitate the development of novel
approaches for targeted surveillance as well as early intervention
strategies in HCT survivors at highest risk for A-CHF.60
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We analyzed the incidence and the risk factors of secondary solid
tumors for 17,997 adult recipients (5,598 related bonemarrow recip-
ients, 3,747 related peripheral blood recipients, 6,530 unrelated bone
marrow recipients, 2,093 unrelated cord blood recipients) in Japan.
The subjects were first transplants from 1974 to 2007, whose median
age at transplant was 40 years (range, 16-85), 59% were male, and
their diagnosis at transplant were 57% acute leukemia, 14% chronic
leukemia, 10%myelodysplastic syndrome, 10% lymphoproliferativeS174disorders, and 9% others. 76% received myeloablative conditioning
regimen before transplant, and 68% received total body irradiation.
121 recipients were diagnosed with secondary solid cancer. Solid
tumors in multiple organs were observed in 8 patients. Cumulative
incidence of secondary solid cancer was 0.6% (95% confidence inter-
val [CI], 0.4- 0.7%) at 5 years, and 1.1% (95%CI, 0.9-1.4 %) at 10
years after transplant. The risk of secondary solid tumor was signif-
icantly higher when compared to general population in Japan (ob-
served / expected ratio [O/E]1.3, 95%CI, 1.1-1.6). The risk was
significantly higher for oral cancer (O/E 5 12.4, 95%CI, 8.5-
17.4), esophagus cancer (O/E 5 5.6, 95%CI, 3.2-9.1), gall bladder
cancer (O/E 5 3.4, 95%CI, 1.1-7.9), and skin cancer (O/E 5 6.8,
95%CI, 2.7-14.0) compared to general population.
Multivariate analyses revealed chronic graft-versus-host disease
(CGVHD) was the sole significant riskfactor for developing solid tu-
mor (RR 5 1.6, 95%CI, 1.1-2.4 p 5 0.017) among recipients who
survived at least one year post transplant. CGVHD was present in
75% (24/32) of oral cancer patients, 81% (13/16) of esophagus can-
cer patients, 60% (3/5) of gall bladder cancer patients, and 71% (5/7)
of skin cancer patients. CGVHD significantly increased the risk of
oral cancer (RR 5 2.8, 95%CI, 1.3-6.5, p 5 0.013), and esophagus
cancer (RR 5 4.1, 95%CI, 1.1-14.5, p 5 0.03).
There was significantly higher risk of developing secondary solid
cancer for recipients of allogeneic hematopoietic stem cell transplant
compared to general population. It is important to perform screen-
ing tests for high risk organs for patients with CGVHD.61
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Background: CVD contributes to the increased risk of late non-
relapse mortality after HCT. From indirect measures of IR, some
studies suggest that cancer and HCT survivors may be at higher
risk for IR and subsequently CVD, but the relationship to body
composition has not been delineated.
Methods: Direct measurement of IR (euglycemic hyperinsulinemic
clamp adjusted for lean body mass [LBM, Mlbm], fasting glucose, in-
sulin, lipids, blood pressure (BP), anthropometry, body composition
(DXA scans), were determined in 119 children and young adults (cur-
rent mean age 26.1(60.8) yr, 61.3%male) who had received HCT for
hematologic malignancy during childhood (mean age atHCT12.2 yr,
60.6) and 81 healthy sibling controls (current mean age 22.8(60.9)yr,
49.4% male). All received myeloablative preparative regimens; 90 had
related/unrelated donors and 29 autologous. Mean time after HCT to
assessment was 13.8(60.7)yr. Diagnoses included AML (n5 45), ALL
(n5 34), CML (n5 14), MDS (n5 8), lymphoma (n5 18). Seventy-
two (60.5%) received TBI, 23 (19.3%) received cranial radiation
(CRT) prior to TBI (TBI1CRT), and 24 (20.2%) no XRT before
or during HCT. Linear regression models were used to evaluate
adjusted comparisons of CVD risk factors between groups.
Results:Compared to siblings,HCT survivors had lowerweight but
no differences in BMI or waist circumference. HCT survivors had
higher percent fat mass (PFM) and lower LBM, were significantly
more IR (YMlbm) and had higher fasting insulin levels. Total choles-
terol (TC), low-density lipoprotein cholesterol (LDL-C) and triglyc-
erides (TG) were significantly higher, although high-density
lipoprotein cholesterol (HDL-C) and BP did not differ. When
groups defined by radiation exposure were compared, survivors
who had TBI1CRT were more IR and had higher TC, LDL-C,
TG, fasting glucose and insulin, and lower HDL-C than siblings;
those who received TBI only had higher TC and TG. Survivors
who received no XRT had a CVD risk profile similar to contols.
CVDrisk profile of autologous vs. allogeneic recipients did not differ.
Conclusions: Even at a young age, HCT survivors have increased
CVD risk factors which are independent of obesity, but may be re-
lated to alterations in body composition (YLBM and [PFM), IR
Oral Presentations S175and exposure to TBI 6CRT. These factors may contribute to
a higher risk of early CVD morbidity and mortality suggesting
that screening and management of modifiable CVD risk factors
should be initiated in HCT survivors.
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†adjusted for age-at-study, sex, race, and Tanner, and PFM.
‡P-values for comparison to Controls.
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RISK FACTORS FOR LATE CARDIOVASCULAR MORBIDITY AND
MORTALITY AFTER HEMATOPOIETIC CELL TRANSPLANTATION
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cer Research Center, Seattle, WA; 2University of Washington, Seattle,
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Purpose: To examine the effect of pre-transplant treatment and
transplant related-risk factors for late cardiovascular (CV) disease
following hematopoietic cell transplantation (HCT).
Methods: Nested case-cohort study. All 2 yr HCT survivors who
were Washington State residents treated at the Fred Hutchinson
Cancer Research Center from 1985-2006 (n 5 1491; 56% alloge-
neic, 44% autologous) were linked to the state’s hospital discharge
and death registries beginning 2 yrs after HCT (1987-2008). Deathses Associate
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c/autologous dand hospitalizations due to selected CV diagnoses (ischemic heart
disease, cardiomyopathy, dysrhythmia, stroke and other vascular dis-
ease) and related conditions (hypertension, dyslipidemia, diabetes,
renal disease/dialysis) were identified. Relationships (hazard ratios,
HR) among treatment risk factors and CV outcomes were examined
between affected survivors (cases, n 5 436) and a randomly selected
subset of the remaining HCT cohort (n 5 371).
Results: Among these 807 survivors, median age at HCT was 41 (0-
73) yrs and time to event was 5 (2-24) yrs. Individual CV events in-
cluded: 39 CV-related deaths, 56 ischemic heart disease, 80 cardiomy-
opathy, 109 dysrhythmia, 33 stroke, and 52 other vascular disease. In
multivariable models, survivors with cumulative anthracycline expo-
sures $ 300 mg/m2 were more likely to experience CV death (HR
2.8, 95% CI 1.0-7.6), cardiomyopathy (HR 2.1, 95% CI 1.0-4.4),
and dysrhythmia (HR 1.9, 95% CI 1.1-3.3). The association between
anthracycline dose and CV outcomes appeared greater following allo-
geneic than autologous HCT. Allogeneic HCT also was associated
with increased risk of hypertension (HR1.6, 95%CI1.1-2.3), with un-
related donorHCTand chronic graft versus host disease (GVHD) be-
ing significant risk factors. Total body irradiation and chest radiation
were not independently associated with anyCVoutcome. In sub-anal-
yses, survivors with dyslipidemia 1 yr after HCT had an increased risk
of subsequent ischemic heart disease (HR 8.9, 95% CI 3.1-25.9), and
those with both dyslipidemia and hypertension 1 yr after HCT also
had increased risk of subsequent diabetes (HR 4.3, 95% CI 1.6-11.2).
Conclusions: Increased exposure to pre-HCT anthracyclines was
associated with multiple adverse CV outcomes after HCT, including
CV death. HCTwith unrelated donors and chronic GVHDwere as-
sociated with increased risk of hypertension, but otherHCT-specific
exposures were not consistently associated with additional risk of CV
morbidity.63
EVALUATION OF SCALES CORRELATED WITH CLINICIAN AND PATIENT-
PERCEIVED SYMPTOM CHANGE IN OCULAR GRAFT-VERSUS-HOST DIS-
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Measurement scales used to rate the symptomchange in ocular graft-
versus-host disease (GVHD) have not been validated for use in clinical
trials.
Methods: We compared clinician and patient perceptions of eye
symptom changes based on serial clinician or patient-reportedd with Treatment Exposures, Hazard Ratios (95% CI)
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